Delayed and persistent ERK1/2 activation is required for 4-hydroxytamoxifen-induced cell death

Area of Science:

• Cell Biology
• Molecular Pharmacology
• Cancer Research

Background:

• Tamoxifen (Tam) and its metabolite 4-hydroxytamoxifen (OHT) are anti-estrogenic compounds.
• OHT binds to the estrogen receptor (ER) and can induce ER-dependent apoptosis in cancer cells.
• The precise signaling pathways mediating OHT-ER-induced apoptosis are not fully elucidated.

Purpose of the Study:

• To investigate the role of specific signal transduction pathways (p38, JNK, ERK1/2) in OHT-ER-mediated apoptosis.
• To determine the temporal dynamics of pathway activation and their contribution to cell death.
• To identify key molecular mechanisms underlying OHT's apoptotic effects.

Main Methods:

• Utilized HeLaER6 cells expressing the estrogen receptor.
• Administered OHT and measured ER-dependent apoptosis.
• Employed pathway inhibitors (SB203580 for p38, JNK inhibitor, PD98059 for MEK1/2) and activators (EGF).
• Assessed protein phosphorylation via Western blotting to monitor pathway activation.
• Investigated the effect of antagonist ICI 182,780 on OHT-mediated signaling and apoptosis.

Main Results:

• OHT-ER activated the p38, JNK, and ERK1/2 signaling pathways.
• Inhibition of p38 or JNK pathways only partially reduced OHT-induced apoptosis.
• Complete blockade of OHT-ER-mediated apoptosis was observed with MEK1/2 inhibition (PD98059).
• Epidermal Growth Factor (EGF) enhanced OHT-induced apoptosis.
• OHT induced a delayed and persistent phosphorylation of ERK1/2 (>80 hours).
• Late administration of PD98059 (24 hours) still blocked OHT-induced apoptosis.
• ICI 182,780 inhibited both persistent ERK1/2 phosphorylation and OHT-induced apoptosis.

Conclusions:

• The p38 and JNK pathways play a limited role in OHT-ER-mediated apoptosis.
• Persistent activation of the ERK1/2 pathway is critical and essential for OHT-ER-induced cell death.
• Targeting the ERK1/2 pathway may represent a therapeutic strategy for enhancing OHT efficacy in cancer treatment.